Last edition
News about "China NMPA approval"
Zai Lab Secures China Approval for TIVDAK
Zai Lab has received China NMPA approval for TIVDAK (tisotumab vedotin), the first Antibody-Drug Conjugate (ADC) approved for previously treated recurrent or metastatic cervical cancer in China. The approval is supported by phase 3 innovaTV 301 trial data demonstrating a statistically significant overall survival benefit.
China NMPA Approval | 09/06/2026 | By News Bureau
Lupin Secures China Approval for Oseltamivir Phosphate Oral Suspension
Lupin receives approval in China for Oseltamivir Phosphate Oral Suspension 6 mg/mL, expanding access to influenza treatment, particularly for pediatric patients.
China NMPA Approval | 25/05/2026 | By News Bureau | 108
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy